


IN VIVO OPTICAL IMAGING

MIR is the only preclinical contract research organization to receive a license from the Xenogen Corporation to perform contract bioluminescence and fluorescence imaging. MIR owns and operates Xenogen's IVIS® imaging system on site.



Cells or animals can be genetically altered to express genes for fluorescent proteins or enzymes capable of activating a luminescent substrate. These genes can be constitutively expressed to indicate tumor burden or conditionally expressed and used as a reporter for a specific gene or function of interest. MIR has a number of proprietary preclinical assays to non-invasively assess drug function. MIR can utilize fluorescence and bioluminescence to measure:

- Tumor Diagnosis
- Metastatic Events
- Cellular Proliferation
- Physiological Changes
- Apoptosis
- P53 Activation
- Gene Expression



Innovation in Drug
Evaluation

MIR Preclinical Services

